CRISPR–Cas9 in Chronic Lymphocytic Leukemia with Mutant P53
The International Cancer and Precision Oncology Conference 2026 continues to highlight
transformative advancements in cancer research. This presentation focuses on
the role of CRISPR–Cas9 gene-editing technology in treating chronic
lymphocytic leukemia (CLL).
🎤 Speaker
Aurelian
Udristioiu
Titu Maiorescu University of Bucharest, Romania
▶️ Watch Presentation
https://www.youtube.com/watch?v=HoPj5mZdPUA
🧾 Abstract (Summary)
This
scientific presentation explores how CRISPR–Cas9 technology can be
applied to target and correct mutations in the P53 gene, a critical
factor in the progression of chronic lymphocytic leukemia (CLL).
Key Highlights:
- Application of CRISPR–Cas9
in cancer gene editing
- Targeting mutant P53 gene in
CLL patients
- Enhancing therapeutic
precision in oncology
- Potential to improve
treatment outcomes
- Ethical and clinical
challenges in gene-editing therapies
This work
represents a significant step toward precision medicine and personalized
cancer treatment strategies.
🔗 Conference Links
🌐 Official Website: https://cancer.miconferences.com/
📑 Scientific Program:
https://cancer.miconferences.com/program
📩 Contact Email: info@mathewsconference.com
💬 WhatsApp: +1 (424) 377 0967
🏢 Organizer: https://miconferences.com/
📍 Conference Details
International
Cancer and Precision Oncology Conference 2026
📆 November 23–25, 2026
📍 Singapore & Online
🔖 Hashtags
#ICPOC2026
#CRISPRCas9 #GeneEditing #LeukemiaResearch #CLL #CancerResearch #Oncology
#PrecisionMedicine #MedicalInnovation #CancerScience
